- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Pfizer Ratings Report.
Shares of Bristol-Myers Squibb are higher during trading on Monday, after Jefferies reiterated its 'buy' rating, but analysts are mixed on the call.
A possible merger between Nestle and Mead Johnson could trigger anti-trust concerns.
Pfizer is working on its eighth straight loss after failing near heavy resistance.
Shares of Pfizer have been on the decline, losing some 5% from its January 5 high of $33.61 a share.